High Court Refuses Bid To Hear Prilosec Patent Spat

Law360, New York (October 3, 2006, 12:00 AM EDT) -- The U.S. Supreme Court on Monday declined to intervene in a long-running patent dispute between Swedish-U.K. drug manufacturer AstraZeneca AB and Impax Laboratories involving the gastrointestinal treatment drug Prilosec OTC.

On Monday, the high court denied a petition for writ of certiorari by the Hayward, Calif.-based Impax, which has been involved in litigation with AstraZeneca over Prilosec, once the world’s best-selling drug, since 2000.

The legal wrangling began when AstraZeneca sued Impax in the U.S. District Court for the District of Delaware on the heels of...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.